Express News | The Tanzania Investment Center China (Hunan) Investment Cooperation Platform has been launched.

BreakingsDec 14 12:46

Medical and healthcare stocks fluctuated and rose, hunan er-kang pharmaceutical surged more than 15%.

Gelonghui on December 6th: Medical and healthcare stocks fluctuated upwards, with Hunan Er-kang Pharmaceutical rising by over 15%. Dezhan Healthcare, Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd., Harbin Gloria Pharmaceuticals had previously hit the limit up, while Porton Pharma Solutions, Iray Technology, Huada Intelligent Manufacturing, and others rose by over 5%.

Gelonghui FinanceDec 6 13:19

Erkang Pharmaceuticals: Report for the third quarter of 2024

SZSIOct 25 00:00 · Announcements

hunan er-kang pharmaceutical (300267.SZ): a net loss of 31.7675 million yuan in the third quarter.

On October 24, Gelonhui reported that Hunan Er-Kang Pharmaceutical (300267.SZ) achieved revenue of 0.233 billion yuan in the third quarter of 2024, a year-on-year decrease of 41.06%; net income attributable to shareholders of the listed company was -31.7675 million yuan; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -34.3959 million yuan; basic earnings per share was -0.0154 yuan.

Gelonghui FinanceOct 24 16:54

Concept Mining | A major breakthrough in the "longevity drug", will concept stocks usher in a period of outbreak?

Increase by 100 times.

Gelonghui FinanceOct 24 12:16

A-share macrobiotic nmn concept stocks continue to rise, xiamen kingdomway group hits the limit up.

On October 24, Xiamen Kingdomway Group hit the daily limit, Aba Chemicals Corporation rose by more than 10%, Hunan Er-Kang Pharmaceutical, Guangdong Zhongsheng Pharmaceutical, Brother Enterprises Holding, dezhan healthcare and others led the gainers. On the news front, according to the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, the institute has achieved over a 100-fold increase in the production of nicotinamide mononucleotide (NMN) by developing a de novo synthesis pathway. Reports indicate that Tianjin Institute of Industrial Biotechnology successfully developed a de novo synthesis pathway for NMN in E. coli through systematic engineering, effectively increasing the in vivo metabolic production of NMN.

Gelonghui FinanceOct 24 09:34